Stratistics MRC¿¡ µû¸£¸é, ¼¼°è ¹é½Å º¸°ü ¹× Æ÷Àå ½ÃÀåÀº 2025³â¿¡ 400¾ï 6,000¸¸ ´Þ·¯ ±Ô¸ðÀ̸ç, 2032³â¿¡´Â 885¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 12.0%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¹é½ÅÀÇ º¸°ü ¹× Æ÷ÀåÀº Á¦Á¶ºÎÅÍ Åõ¿©±îÁö ¹é½ÅÀÇ À¯È¿¼º°ú ¾ÈÀü¼ºÀ» À¯ÁöÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀûÀýÇÑ º¸°ü Á¶°Ç, ƯÈ÷ ¿Âµµ °ü¸®´Â ¹é½ÅÀÇ È¿´ÉÀ» À¯ÁöÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇϱ⠶§¹®¿¡ ÄݵåüÀÎ ¹°·ù, Áï ¹é½ÅÀÌ Á¤ÇØÁø ¿Âµµ ¹üÀ§ ³»¿¡ ÀÖµµ·Ï º¸ÀåÇÏ´Â ³ÃÀå ½Ã½ºÅÛÀº ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ, º¯Á¶ ¹æÁö ¾Á ¹× ¿Âµµ °¨Áö ¶óº§°ú °°Àº Æ÷Àå ±â¼ú Çõ½ÅÀ¸·Î ÀÎÇØ ÃßÀû¼º°ú º¸¾ÈÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¿¹¹æÁ¢Á¾¿¡ ´ëÇÑ ³ë·ÂÀÌ È®´ëµÊ¿¡ µû¶ó ½Å·ÚÇÒ ¼ö ÀÖ°í È¿°úÀûÀ̸ç Áö¼Ó°¡´ÉÇÑ ¹é½Å º¸°ü ¹× Æ÷Àå ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä´Â ƯÈ÷ °í¸³µÈ Àú°³¹ß Áö¿ª¿¡¼ ´õ¿í Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¹ü¹Ìº¸°Ç±â±¸(PAHO)¿¡ µû¸£¸é, ¹é½Å ¹ÙÀÌ¾Ë ¸ð´ÏÅÍ(VVM)´Â ÁöÁ¤µÈ ÀÓ°èÄ¡ ÀÌ»óÀÇ ¿Âµµ¿¡ ³ëÃâµÇ¸é »öÀÌ º¯ÇÏ´Â ¿ Ç¥½Ã±âÀ̸ç, 5°¡Áö À¯ÇüÀÇ VVMÀÌ ÀÖÀ¸¸ç, °¢ À¯ÇüÀº ¿ ¾ÈÁ¤¼º¿¡ µû¶ó ƯÁ¤ ¹é½Å¿¡ ¸Â°Ô ¼³°èµÇ¾ú½À´Ï´Ù. ÀÌ VVMÀº 37¡É, 25¡É, 5¡ÉÀÇ ¼¼ °¡Áö ¿Âµµ ÀÓ°è°ªÀ¸·Î ºÐ·ùµË´Ï´Ù.
Àü ¼¼°è ¿¹¹æÁ¢Á¾ ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡
¹é½Å º¸°ü ¹× Æ÷Àå ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â ¼±Áø±¹°ú ½ÅÈï±¹À» ¸··ÐÇÏ°í ¿¹¹æÁ¢Á¾ Ä·ÆäÀÎÀÌ È®»êµÇ°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO), Gavi, À¯´Ï¼¼ÇÁ µîÀÇ ´Üü´Â È«¿ª, ¼Ò¾Æ¸¶ºñ, HPV, COVID-19¿Í °°Àº Áúº´À» ÅðÄ¡Çϱâ À§ÇÑ Áý´Ü ¿¹¹æÁ¢Á¾ Ä·ÆäÀο¡ ¸Å³â ¼ö½Ê¾ï ´Þ·¯¸¦ ÁöÃâÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â ÇöÀç Gavi´Â 9¾ï 8,100¸¸ ¸í ÀÌ»óÀÇ ¾î¸°À̵鿡°Ô ¹é½Å Á¢Á¾À» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ³ë·ÂÀÇ °á°ú·Î Ư¼ö º¸°ü ½Ã½ºÅÛ ¹× º¸È£ Æ÷Àå ¼Ö·ç¼ÇÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¹é½ÅÀÇ È¿´ÉÀ» º¸ÀåÇϱâ À§ÇØ ¾ö°ÝÇÑ ¿Âµµ ¹× ¾ÈÀü °ü¸®¸¦ °®Ãá ½Å·ÚÇÒ ¼ö ÀÖ´Â °ø±Þ¸ÁÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù.
³ôÀº ¿î¿µºñ¿Í ÀÚº» ºñ¿ë
¹é½Å º¸°ü ½Ã½ºÅÛ, ƯÈ÷ ÃÊÀú¿Â ¹°·ù¸¦ »ç¿ëÇÏ´Â ¹é½Å º¸°ü ½Ã½ºÅÛÀº ¼³Ä¡ ¹× À¯Áöº¸¼ö¿¡ ºñ¿ëÀÌ ¸¹ÀÌ µì´Ï´Ù. ƯÈ÷ ÀÚ¿øÀÌ ÇÑÁ¤µÈ ȯ°æ¿¡¼´Â Ư¼ö ³Ãµ¿°í, ´Ü¿ ¿ë±â, ¸ð´ÏÅ͸µ ÀåºñÀÇ ±¸¸Å ¹× ¿î¿µ¿¡ ¸¹Àº ºñ¿ëÀÌ ¼Ò¿äµË´Ï´Ù. ¶ÇÇÑ, ÀÏÁ¤ÇÑ Àú¿ÂÀ» À¯ÁöÇϱâ À§ÇØ ÇÊ¿äÇÑ Àü·ÂÀ¸·Î ÀÎÇØ ¹Ýº¹ÀûÀÎ ¿î¿µ ºñ¿ëµµ Áõ°¡ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, ÃÊÀú¿Â(ULT) ³Ãµ¿°í´Â ´ë´ç 1¸¸ ´Þ·¯¿¡¼ 2¸¸5õ ´Þ·¯¿¡ ´ÞÇϸç, ±âÁ¸ ³Ãµ¿ ½Ã½ºÅÛº¸´Ù ´õ ¸¹Àº ¿¡³ÊÁö¸¦ »ç¿ëÇÕ´Ï´Ù. ƯÈ÷ ÀÚ¿ø°ú ÀÎÇÁ¶ó°¡ ºÎÁ·ÇÑ °³¹ßµµ»ó±¹, ¼Ò±Ô¸ð º´¿ø, ½Ã°ñ Áø·á¼Ò¿¡¼´Â ÀÌ·¯ÇÑ ºñ¿ë ¶§¹®¿¡ µµÀÔÀÌ Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù.
½º¸¶Æ® Æ÷ÀåÀÇ Ã·´Ü ±â¼ú
½Ç½Ã°£ ¸ð´ÏÅ͸µ ¼¾¼, RFID ű×, ¿Âµµ °¨Áö ¶óº§, QR Äڵ带 ÅëÇÑ ÃßÀû¼ºÀº ³Î¸® º¸±ÞµÇ°í ÀÖ´Â ½º¸¶Æ® Æ÷Àå ¼Ö·ç¼ÇÀÇ ÇÑ ¿¹ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº °ø±Þ¸ÁÀÇ Åõ¸í¼ºÀ» Çâ»ó½Ã۰í, ÀÎÀû ¿À·ù¸¦ ÁÙÀ̰í, ¾ÈÀü¼ºÀ» ³ôÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, WHO°¡ Áö¿øÇÏ´Â ¹é½Å Á¢Á¾ Ä·ÆäÀÎÀº ÇöÀç ¿¿¡ ³ëÃâµÇ¸é »öÀÌ º¯ÇÏ´Â ¹é½Å ¹ÙÀÌ¾Ë ¸ð´ÏÅÍ(VVM)¸¦ ÀÏ»óÀûÀ¸·Î »ç¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±â¾÷µéÀº IoT ¹× AI ±â¹Ý ÃßÀûÀ» ÆÐŰÁö¿¡ ÅëÇÕÇÔÀ¸·Î½á È¥ÀâÇÑ ½ÃÀå¿¡¼ Á¦Ç°À» Â÷º°ÈÇÏ°í ºÎ°¡°¡Ä¡ ¼ºñ½º¸¦ Á¦°øÇÏ´Â »õ·Î¿î ¹æ¹ýÀ» ¾ò°Ô µÇ¾ú½À´Ï´Ù.
°ø±Þ¸Á È¥¶õÀÌ ¹é½Å ³¶ºñ¸¦ ÃÊ·¡ÇÏ´Â ¿øÀÎ
±â¼úÀÇ ¹ßÀü¿¡µµ ºÒ±¸ÇÏ°í °ø±Þ¸ÁÀÇ Ãë¾à¼ºÀº ¿©ÀüÈ÷ À§ÇùÀÌ µÇ°í ÀÖ½À´Ï´Ù. Àåºñ °íÀå, ¼¼°ü Áö¿¬, ºÒÃæºÐÇÑ ¿î¼Û ÀÎÇÁ¶ó, Á¤ÀüÀ¸·Î ÀÎÇÑ ¿Âµµ º¯È·Î ÀÎÇØ ¹é½ÅÀÇ È¿´ÉÀÌ ¼Õ»óµÉ ¼ö ÀÖÀ¸¸ç, WHOÀÇ ÃßÁ¤¿¡ µû¸£¸é Àü ¼¼°èÀûÀ¸·Î ÃÖ´ë 50%ÀÇ ¹é½ÅÀÌ Æó±âµÇ°í ÀÖÀ¸¸ç, ´ëºÎºÐ Ãë±Þ ¹× ¿Âµµ °ü¸® ¹®Á¦·Î ÀÎÇØ Æó±âµÇ°í ÀÖ½À´Ï´Ù. ±× °á°ú Á¦Á¶¾÷ü¿Í Á¤ºÎ´Â °æÁ¦Àû ¼Õ½ÇÀ» ÀÔ°Ô µÇ°í, º¸°ü ½Ã½ºÅÛÀº ½Å·Ú¸¦ ÀÒ°Ô µË´Ï´Ù. ¶ÇÇÑ, ÄݵåüÀÎ ¼º´ÉÀÇ ÆíÂ÷°¡ Àֱ⠶§¹®¿¡ °í±Þ Æ÷Àå ¹× º¸°ü ±â¼ú Çõ½Å¿¡ ´ëÇÑ Ãß°¡ ÁöÃâÀÌ ¾ïÁ¦µË´Ï´Ù.
COVID-19 ÆÒµ¥¹ÍÀº Àü ¼¼°èÀûÀ¸·Î Á¤±³ÇÑ ÆÐŰ¡°ú ÄݵåüÀÎ ÀÎÇÁ¶ó¿¡ ´ëÇÑ ¾öû³ ¼ö¿ä¸¦ âÃâÇÏ¿© ¹é½Å º¸°ü ¹× Æ÷Àå ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÈÀÌÀÚ ¹ÙÀÌ¿ÀÅØ, ¸ð´õ³ª µî ±ØÀú¿Â º¸°üÀÌ ÇÊ¿äÇÑ ¹é½ÅÀÇ ½Å¼ÓÇÑ °³¹ß°ú º¸±ÞÀº Ư¼ö ³Ãµ¿°í, ´Ü¿ Æ÷Àå ½ÃÆÛ, µå¶óÀ̾ÆÀ̽º Æ÷Àå, ½Ç½Ã°£ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ µî¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇß½À´Ï´Ù. Á¤ºÎ, Á¦¾àȸ»ç, ¹°·ù¾÷üµéÀÇ »ý»ê´É·ÂÀÇ ±Þ¼ÓÇÑ È®ÀåÀº ½ÃÀåÀÇ ±Þ°ÝÇÑ È®´ë·Î À̾îÁ³½À´Ï´Ù. ¶ÇÇÑ, ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ ÁßÀú¼Òµæ ±¹°¡ÀÇ ÄݵåüÀÎ ±â´ÉÀÇ °áÇÔÀÌ µå·¯³ª¸é¼ ÈÞ´ë¿ë ¹× ¿¡³ÊÁö È¿À²ÀûÀÎ ÀúÀå Àåºñ¿¡ ´ëÇÑ Àü ¼¼°èÀûÀÎ ÅõÀÚ¿Í ¹ßÀüÀÌ ÀÌ·ç¾îÁ³½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ÇÃ¶ó½ºÆ½ ºÎ¹®ÀÌ °¡Àå Ŭ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÇÃ¶ó½ºÆ½ ºÎ¹®Àº Àú·ÅÇÑ °¡°Ý, °ß°í¼º, È޴뼺À¸·Î ÀÎÇØ ±¤¹üÀ§ÇÑ ¹é½Å ¹èÆ÷¿¡ ÀûÇÕÇϱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇÃ¶ó½ºÆ½Àº À¯¸®¿¡¼ Å« ¹®Á¦°¡ µÇ´Â ±úÁö±â ½¬¿î Ư¼ºÀ¸·Î ÀÎÇØ ¹é½Å¿ë ¹ÙÀ̾Ë, ÁÖ»ç±â, ¾ÚÇÃ, 2Â÷ Æ÷Àå¿¡ ÀÚÁÖ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¹é½Å Æ÷Àå¿¡ »ç¿ëµÇ´Â ÀϹÝÀûÀÎ ÇÃ¶ó½ºÆ½¿¡´Â ȯÇü ¿Ã·¹ÇÉ °øÁßÇÕü(COC), Æú¸®ÇÁ·ÎÇÊ·»(PP), °í¹Ðµµ Æú¸®¿¡Æ¿·»(HDPE) µîÀÌ ÀÖÀ¸¸ç, ¹«±Õ¼º°ú ´Ù¾çÇÑ ¹é½Å Á¦Á¦¿ÍÀÇ È£È¯¼ºÀ» º¸ÀåÇÕ´Ï´Ù. ¶ÇÇÑ, Æú¸®¸Ó ±â¹Ý ÄݵåüÀÎ ¼Ö·ç¼Ç°ú Ư¼ö ´Ü¿ ¿ë±âÀÇ ÀαⰡ ³ô¾ÆÁö°í ÀÖ´Â °Í¿¡¼ ¾Ë ¼ö ÀÖµíÀÌ, ¿Âµµ Á¦¾î ¹°·ù´Â ÇÃ¶ó½ºÆ½ Æ÷Àå¿¡ ÀÇÇØ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù.
mRNA ¹é½Å ºÐ¾ß´Â ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È mRNA ¹é½Å ºÐ¾ß´Â °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ÈÀÌÀÚ ¹ÙÀÌ¿ÀÅØ°ú Moderna µîÀÇ COVID-19 ¹é½ÅÀÇ ¼º°ø°ú »ý¸í°øÇÐ ±â¼úÀÇ ¹ß´Þ¿¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹é½ÅÀº ÃÊÀú¿Â(-70¡É--20¡É)¿¡¼ º¸°üÇØ¾ß Çϱ⠶§¹®¿¡ ´Ü¿ Æ÷Àå ¿ë±â, ¿Âµµ ¸ð´ÏÅ͸µ ±â±â, Ư¼ö ÄݵåüÀÎ Æ÷Àå ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸ÂÃãÇü ÀÇ·á, ¾Ï ¸é¿ªÄ¡·á, °¨¿°¼º Áúȯ¿¡ ´ëÇÑ mRNA ±â¼úÀÇ ±Þ¼ÓÇÑ º¸±ÞÀ¸·Î ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. µ¿°á°ÇÁ¶(µ¿°á°ÇÁ¶) Á¦Á¦ÀÇ ¹ßÀü°ú ÁöÁú ³ª³ëÀÔÀÚÀÇ ¾ÈÁ¤¼º Çâ»óÀ¸·Î º¸Á¸ÀÇ Çʿ伺Àº ÁÙ¾îµé°ÚÁö¸¸, ÃÊÄݵåüÀÎ ÀÎÇÁ¶ó´Â ¿©ÀüÈ÷ Áß¿äÇÕ´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À̴ źźÇÑ Á¤ºÎ ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥, ³ôÀº ¹é½Å »ý»ê·®, ³ôÀº ¼öÁØÀÇ ÄݵåüÀÎ ÀÎÇÁ¶ó°¡ ±¸ÃàµÇ¾î Àֱ⠶§¹®ÀÔ´Ï´Ù. Pfizer, Moderna, Johnson & Johnson°ú °°Àº ´ëÇü Á¦¾àȸ»çµéÀÇ Á¸Àç¿Í FDA ¹× CDCÀÇ ±ÔÁ¦ Áö¿øÀ¸·Î ÀÎÇØ Ư¼ö º¸°ü ¹× Æ÷Àå ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ªÀÇ ½ÃÀå ÁöÀ§´Â È®¸³µÈ ÃÊÀú¿Â üÀÎ ¹°·ù¸¦ ÅëÇØ °¡´ÉÇØÁø COVID-19 ¹é½ÅÀÇ ´ë·® À¯ÅëÀ¸·Î ÀÎÇØ ´õ¿í °ÈµÇ¾ú½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀº °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ÀǾàǰ »ý»ê Áõ°¡, ÄݵåüÀÎ ÀÎÇÁ¶ó °È, ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ÀÇ ±Þ°ÝÇÑ ¼ºÀå µî¿¡ ±âÀÎÇÕ´Ï´Ù. Áß±¹, Àεµ, ÀϺ»°ú °°Àº ±¹°¡µéÀº Áý´Ü ¿¹¹æÁ¢Á¾ ³ë·ÂÀ» Áö¿øÇϱâ À§ÇØ ¹é½Å »ý»ê, ¿Âµµ °ü¸® ¹°·ù, »ý¸í°øÇÐ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ÀÎÇÁ¶ó¸¦ °³¼±Çϱâ À§ÇÑ Á¤ºÎÀÇ ³ë·Â°ú °¨¿°¼º Áúȯ¿¡ ´ëÇÑ ¹é½Å ¼ö¿ä Áõ°¡·Î ÀÎÇØ ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ªÀÇ ±Þ°ÝÇÑ ¼ºÀåÀº Áö¿ª ¹é½Å Á¦Á¶¾÷üÀÇ ÃâÇö°ú ´Ü¿ Æ÷Àå ¿ë±â ¹× ½º¸¶Æ® ¶óº§°ú °°Àº ÷´Ü Æ÷Àå ±â¼úÀÇ »ç¿ëÀ¸·Î ÀÎÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.
According to Stratistics MRC, the Global Vaccine Storage & Packaging Market is accounted for $40.06 billion in 2025 and is expected to reach $88.57 billion by 2032 growing at a CAGR of 12.0% during the forecast period. Vaccine storage and packaging play a critical role in maintaining the efficacy and safety of vaccines from production to administration. Cold chain logistics, or refrigeration systems that guarantee vaccines stay within a predetermined temperature range, are crucial because proper storage conditions, especially temperature control, are crucial to maintaining vaccine potency. Moreover, improved traceability and security have resulted from packaging innovations like tamper-evident seals and temperature-sensitive labels. Demand for reliable, effective, and sustainable vaccine storage and packaging solutions is going to increase as global immunization efforts spread, particularly in isolated and underdeveloped regions.
According to the Pan American Health Organization (PAHO), vaccine vial monitors (VVMs) are heat indicators that change color when exposed to temperatures above a specified threshold. There are five different types of VVMs, each designed for specific vaccines based on their heat stability. These VVMs are classified using three temperature thresholds: 37°C, 25°C, and 5°C.
Increasing worldwide immunization initiatives
One of the main factors propelling the vaccine storage and packaging market is the spread of immunization campaigns in both developed and developing nations. Every year, billions of dollars are spent on mass vaccination campaigns to combat diseases like measles, polio, HPV, and COVID-19 by groups like the World Health Organization (WHO), Gavi, and UNICEF. As of 2023, for instance, Gavi has facilitated the vaccination of more than 981 million children. Additionally, the need for specialized storage systems and protective packaging solutions is increased as a result of these efforts, which call for a highly dependable supply chain with stringent temperature and safety controls to guarantee vaccine potency.
High operating and capital expenses
Vaccine storage systems, especially those that use ultra-cold chain logistics, are expensive to set up and maintain. Particularly in environments with limited resources, specialized freezers, insulated containers, and monitoring equipment are costly to purchase and run. Recurring operating costs are also increased by the electricity needed to maintain constant low temperatures. Ultra-low temperature (ULT) freezers, for example, can cost anywhere from $10,000 to $25,000 per unit and use a lot more energy than conventional refrigeration systems. Furthermore, adoption may be restricted by these expenses, particularly in developing nations with limited resources and infrastructure, small hospitals, and rural clinics.
Technological advancements in smart packaging
Real-time monitoring sensors, RFID tags, temperature-sensitive labels, and traceability enabled by QR codes are examples of smart packaging solutions that are becoming more and more popular. These technologies improve supply chain transparency, lower human error, and increase safety. For example, vaccination campaigns supported by the WHO now routinely use vaccine vial monitors (VVMs), which change color when exposed to heat. Moreover, businesses now have new ways to differentiate their products in a crowded market and offer value-added services by integrating IoT and AI-based tracking into packaging.
Disruptions in the supply chain cause vaccine waste
Supply chain vulnerabilities continue to pose a threat in spite of technological advancements. The effectiveness of vaccines may be compromised by temperature excursions brought on by equipment failures, delays at customs, inadequate transportation infrastructure, and power outages. The WHO estimates that up to 50% of vaccines are thrown away worldwide, mostly as a result of handling and temperature control problems. Manufacturers and governments suffer financial losses as a result, and storage systems lose their credibility. Additionally, inconsistent cold chain performance discourages additional spending on upscale packaging and storage innovations.
The COVID-19 pandemic significantly impacted the vaccine storage and packaging market by creating an unparalleled demand for sophisticated packaging and cold chain infrastructure worldwide. The quick development and widespread use of vaccines that needed to be stored at extremely low temperatures, such as Pfizer-BioNTech and Moderna, prompted investments in specialized freezers, insulated shippers, dry ice packaging, and real-time monitoring systems. Rapid capacity expansion by governments, pharmaceutical firms, and logistics providers led to a spike in market expansion. Furthermore, the pandemic brought to light deficiencies in cold chain capabilities in low- and middle-income nations, which led to global investment and advancements in portable and energy-efficient storage devices.
The plastic segment is expected to be the largest during the forecast period
The plastic segment is expected to account for the largest market share during the forecast period because of its affordability, robustness, and portability, which make it perfect for widespread vaccination distribution. Because of its resistance to breaking, which is a big issue with glass, it is frequently used in vaccine vials, syringes, ampoules, and secondary packaging. Common plastics used in vaccine packaging include cyclic olefin copolymer (COC), polypropylene (PP), and high-density polyethylene (HDPE), which guarantee sterility and compatibility with various vaccine formulations. Moreover, temperature-controlled logistics are supported by plastic packaging, as evidenced by the growing popularity of polymer-based cold chain solutions and specialized insulated containers.
The mRNA vaccines segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the mRNA vaccines segment is predicted to witness the highest growth rate, motivated by the success of COVID-19 vaccines like Pfizer-BioNTech and Moderna, as well as developments in biotechnology. Because these vaccines must be stored at extremely low temperatures (-70°C to -20°C), there is a greater need for insulated containers, temperature monitoring equipment, and specialized cold chain packaging solutions. Additionally, the market is expanding due to the quick uptake of mRNA technology in personalized medicine, cancer immunotherapy, and infectious diseases. Storage needs should be lessened by advancements in lyophilized (freeze-dried) formulations and enhanced lipid nano particle stability, but ultra-cold chain infrastructure is still crucial.
During the forecast period, the North America region is expected to hold the largest market share, driven by robust government immunization programs, high vaccine production, and sophisticated cold chain infrastructure. The need for specialized storage and packaging solutions has increased due to the presence of major pharmaceutical companies like Pfizer, Moderna, and Johnson & Johnson as well as regulatory support from the FDA and CDC. Furthermore, the region's market position was further strengthened by the mass distribution of COVID-19 vaccines, which was made possible by its well-established ultra-cold chain logistics.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by growing pharmaceutical production, enhancing cold chain infrastructure, and quickly growing immunization programs. To support mass immunization efforts, nations like China, India, and Japan are making significant investments in vaccine production, temperature-controlled logistics, and biotechnology research and development. The market is expanding as a result of government initiatives to improve healthcare infrastructure and the rising demand for vaccines against infectious diseases. Moreover, the region's rapid growth is also facilitated by the emergence of regional vaccine producers and the use of cutting-edge packaging technologies like insulated shipping containers and smart labels.
Key players in the market
Some of the key players in Vaccine Storage & Packaging Market include Corning, Inc., Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Stevanato Group, Dulas Ltd., Azenta Inc., Cardinal Health Inc., PHC Holdings Corporation, Blue Star Limited, Panasonc Healthcare Co., Ltd, Nipro Corporation, Standex International Corporation, Eppendorf SE, Gerresheimer AG and Haier Biomedical.
In February 2025, Thermo Fisher Scientific Inc. announced that the company has entered into a definitive agreement with Solventum to acquire Solventum's Purification & Filtration business for approximately $4.1 billion in cash. Solventum's Purification & Filtration business is a leading provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications.
In October 2024, BD (Becton, Dickinson and Company) announced it has reached an agreement to resolve the vast majority of its existing hernia litigation. Terms of the settlement agreement, which are confidential, include cases in both the Rhode Island consolidated litigation and the federal multidistrict litigation in Ohio.
In August 2024, Corning Incorporated and Lumen have announced an agreement for a substantial supply of next-generation optical cable. The agreement reserves 10% of Corning's global fiber capacity for each of the next two years to interconnect AI-enabled data center.